Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: rivastigmine

« Back to Dashboard

Summary for Generic Name: rivastigmine

Tradenames:2
Patents:3
Applicants:7
NDAs:9
Drug Master File Entries: see list27
Suppliers: see list3
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: rivastigmine

Tentative approvals for RIVASTIGMINE

Applicant Application No. Form Dosage
<disabled><disabled>SOLUTION; ORAL2MG/ML
<disabled><disabled>CAPSULE; ORALEQ 1.5MG BASE
<disabled><disabled>CAPSULE; ORALEQ 3MG BASE

Clinical Trials for: rivastigmine

Rivastigmine as a Treatment for Methamphetamine Dependence
Status: Completed Condition: Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Status: Recruiting Condition: Cocaine Dependence; Cocaine Addiction; Cocaine Abuse; Substance Abuse

A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers
Status: Completed Condition: Rivastigmine Toxicity

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Status: Completed Condition: Parkinson's Disease Dementia

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
Status: Completed Condition: Alzheimer Disease

Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
Status: Recruiting Condition: Alzheimer's Dementia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL022083Aug 31, 2012RXNo<disabled><disabled>
Alembic Pharms Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL091689Jun 12, 2012RXNo<disabled><disabled>
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL022083Aug 31, 2012RXNo<disabled><disabled>
Novartis
EXELON
rivastigmine
FILM, EXTENDED RELEASE;TRANSDERMAL022083Jul 6, 2007RXNo6,335,031<disabled>Y<disabled>
Dr Reddys Labs Inc
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL077130Oct 31, 2007RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc